Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Next Previous
Trial Profile

A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE 173; MK-3475-173/KEYNOTE 173
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 11 Mar 2025 Results published in the Breast Cancer Research
  • 25 Nov 2019 Status changed from active, no longer recruiting to completed.
  • 29 Sep 2019 According to Merck's media release KEYTRUDA plus chemotherapy was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top